208 related articles for article (PubMed ID: 3982699)
1. [Evaluation of terminal parathormone NH2 and COOH and plasma calcitonin in the blood of uremic patients under hemodialysis therapy].
Di Landro D; Zanatta GP; Simioni N; Pinzani A; Zotti D; Perin N; Bertoli M; Naso A; Ruffatti A; Gasparotto ML
Minerva Med; 1985 Mar; 76(9-10):419-23. PubMed ID: 3982699
[No Abstract] [Full Text] [Related]
2. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
[No Abstract] [Full Text] [Related]
3. [Correlations between osteodensitometry and parameters of uremic osteodystrophy].
Sforzini S; Viganò MR; Beretta P; Rosa M; d'Amico P; Lomuscio G; Paesani R
Minerva Med; 1985 Mar; 76(9-10):445-8. PubMed ID: 3982703
[No Abstract] [Full Text] [Related]
4. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
[No Abstract] [Full Text] [Related]
5. [Determination of bone mineral content and correlations with calciotropic hormones in periodic hemodialysis patients].
Anelli F; De Maio P; Girardi V; Papagni S; Rossi G; Cantatore FP; Carrozzo M
Minerva Urol Nefrol; 1992; 44(4):265-73. PubMed ID: 1299008
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a relationship between plasma immunoreactive calcitonin and bone disease in chronic renal failure.
Kanis JA; Heynen G; Earnshaw M; Russell RG; Woods CG; Franchimont P; Gaspar S; Oliver D; Ledingham JG
Adv Exp Med Biol; 1977; 81():571-9. PubMed ID: 899941
[No Abstract] [Full Text] [Related]
7. Target levels for serum phosphorus and parathyroid hormone.
Qunibi W; Kalantar-Zadeh K
Semin Dial; 2011; 24(1):29-33. PubMed ID: 21324001
[No Abstract] [Full Text] [Related]
8. Osteodystrophy of dialysed patients treated with vitamin D.
Verberckmoes R; Bouillon R; Krempien B
Proc Eur Dial Transplant Assoc; 1973; 10(0):217-26. PubMed ID: 4370246
[No Abstract] [Full Text] [Related]
9. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
Coen G; Mazzaferro S; Ballanti P; Bonucci E
J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
[No Abstract] [Full Text] [Related]
10. A trial of calcitonin therapy in renal osteodystrophy.
Delano BG; Baker R; Gardner B; Wallach S
Nephron; 1973; 11(5):287-93. PubMed ID: 4753519
[No Abstract] [Full Text] [Related]
11. [Calcitonin for therapy of renal osteodystrophy due to long-term hemodialysis in patients with chronic kidney failure].
Ishida M; Yamada M
Nihon Rinsho; 1991 Dec; 49 Suppl():725-31. PubMed ID: 1808343
[No Abstract] [Full Text] [Related]
12. Influence of calcium infusion on calcitonin and parathyroid hormone concentrations in normal and hemodialyzed subjects.
Isaac R; Nivez MP; Piamba G; Fillastre JP; Ardaillou R
Clin Nephrol; 1975 Jan; 3(1):14-7. PubMed ID: 1126058
[TBL] [Abstract][Full Text] [Related]
13. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
[TBL] [Abstract][Full Text] [Related]
14. Hyperparathyroid bone disease in children undergoing long-term hemodialysis; treatment with vitamin D.
Potter DE; Wilson CJ; Ozonoff MB
J Pediatr; 1974 Jul; 85(1):60-6. PubMed ID: 4852326
[No Abstract] [Full Text] [Related]
15. [Acute effects of hemodialysis on circulating parathormone, osteocalcin and alkaline phosphatase in patients with chronic renal failure].
Broulík P; Hrubý M
Cas Lek Cesk; 1993 Nov; 132(22):681-3. PubMed ID: 8293434
[TBL] [Abstract][Full Text] [Related]
16. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol.
Arora N; Sandroni S; Moles K
Adv Perit Dial; 1992; 8():62-4. PubMed ID: 1361854
[TBL] [Abstract][Full Text] [Related]
17. [Phosphorus and calcium metabolism and its hormonal regulation in chronic kidney failure].
Nikiforova NV; Strunin SE; Ermolenko VM; Mozzhechkov VT; Khomiakova VN
Ter Arkh; 1985; 57(1):103-7. PubMed ID: 3983831
[TBL] [Abstract][Full Text] [Related]
18. Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.
Wang M; Obi Y; Streja E; Rhee CM; Lau WL; Chen J; Hao C; Hamano T; Kovesdy CP; Kalantar-Zadeh K
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1118-1127. PubMed ID: 28487345
[TBL] [Abstract][Full Text] [Related]
19. [Hormonal markers of early-stage osteitis fibrosa in patients on hemodialysis].
Persichetti S; Sagliaschi G; Clemenzia G; Angelitti A; Gallo G; Maggi S; Ponzio R; Punzo G; Tozzo C
Minerva Med; 1992 Nov; 83(11):721-4. PubMed ID: 1461543
[TBL] [Abstract][Full Text] [Related]
20. [Parathyroidectomy in secondary hyperparathyroidism in chronic uremic patients under dialysis treatment. Development of the surgical strategy].
Zucchi C
Minerva Med; 1985 Mar; 76(9-10):397-401. PubMed ID: 3982697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
